Published Studies Related to Travatan (Travoprost)
A short-term randomized clinical trial of daily versus alternate day use of
travoprost 0.004% in the treatment of ocular hypertension. 
in lowering the intraocular pressure (IOP) in patients with ocular hypertension... CONCLUSIONS: Alternate day use of travoprost 0.004% was as safe and effective as
Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. [2011.09]
PURPOSE: The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension... CONCLUSION: Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy. No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. [2011.08]
PURPOSE: To compare the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness (CCT)... CONCLUSIONS: Topical therapy with prostaglandin analogues is associated with CCT reduction. Latanoprost, travoprost, and bimatoprost have a similar effect on CCT.
A 12-week, double-masked, parallel-group study of the safety and efficacy of travoprost 0.004% compared with pilocarpine 1% in Chinese patients with primary angle-closure and primary angle-closure glaucoma. [2011.08]
OBJECTIVE: To examine the intraocular pressure-lowering efficacy and safety of travoprost 0.004% and pilocarpine 1% in Chinese patients with primary angle-closure (PAC) and primary angle-closure glaucoma (PACG) after laser iridotomy in China... CONCLUSIONS: Travoprost 0.004% once daily provides effective IOP-lowering efficacy with significantly greater IOP reduction from baseline when compared with pilocarpine 1% 4 times daily at 4 PM over the 12-week period. Travoprost 0.004% once daily is safe and well tolerated in PAC or PACG patients.
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.
Clinical Trials Related to Travatan (Travoprost)
A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution [Terminated]
The purpose of this study was to assess the pigmentation in the trabecular meshwork of
patients who had been treated for at least 2 years with TRAVATAN compared with patients
without exposure (or less than 1 month) to a prostaglandin analogue (PGA).
Effects of Travatan Z and Xalatan on Ocular Surface Health [Completed]
The purpose of this randomized, double-masked, parallel-group, multicenter study is to
evaluate ocular surface effects after the administration of travoprost with SofZia®
preservative system or Xalatan once daily for 12 weeks.
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension [Completed]
The purpose of this study is to evaluate Travoprost/Brinzolamide fixed combination
(Trav/Brinz) administered twice daily as compared to each of its marketed components
(TRAVATAN Z® solution and AZOPT® suspension) and to the unfixed combination of TRAVATAN Z®
plus AZOPT® in lowering intraocular pressure (IOP).
Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health [Completed]
The purpose of the study is to compare two ophthalmic solutions in patients with open-angle
glaucoma or ocular hypertension.
Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension [Completed]
The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost
New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma
or ocular hypertension.
Reports of Suspected Travatan (Travoprost) Side Effects
Intraocular Pressure Increased (16),
Visual Acuity Reduced (16),
Cystoid Macular Oedema (10),
Vision Blurred (8),
Drug Ineffective (7),
Ocular Hyperaemia (6),
Visual Impairment (5),
Glaucoma (4), more >>